Medical Approach for Weight Loss in Nonalcoholic Fatty Liver Disease
- 22 Downloads
Purpose of Review
Nonalcoholic fatty liver disease (NAFLD) has reached epidemic proportions due to obesity in the modern world. Although treatments are in development, weight loss remains the most definitive and impactful approach to treating this disease and with it the other multisystemic complications of obesity. In this review, we summarize the current medical therapies for weight loss in NAFLD, including patient evaluation, counseling, and incorporation of medications for obesity.
Despite need for weight loss as treatment for NAFLD, few achieve successful weight loss. Weight loss medications lead to weight loss of 5 to 10%, the amount expected to improve NAFLD steatosis and fibrosis. Ultimately, a multimodal approach is necessary to achieve successful weight loss.
Medical management for weight loss in NAFLD requires fibrosis staging and developing a patient-centered approach to assessment of patient weight and behavioral change goals.
KeywordsSteatohepatitis Obesity Pharmacology Weight loss medications Diet Exercise
Body mass index
Endoscopic bariatric therapies
Food and Drug Administration
Nonalcoholic fatty liver
Nonalcoholic fatty liver disease
This work was funded by the National Institutes of Health (NIH T32 DK007017-41 (AD)).
All authors (AD, YCI, and WZM) contributed to research, writing, and editing of this manuscript.
Compliance with Ethical Standards
Conflict of Interest
Albert Do, Ysabel C. Ilagan-Ying, and Wajahat Z. Mehal each declare no potential conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.•• Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11 Global perspective on the epidemiology of NAFLD worldwide with emphasis on growing strain on health-care systems, calling to attention primary care providers, specialists, and health policy makers. PubMedPubMedCentralGoogle Scholar
- 5.• Lindenmeyer CC, McCullough AJ. The natural history of nonalcoholic fatty liver disease-an evolving view. Clin Liver Dis. 2018;22(1):11–21 Review on the elevated risk of NAFLD patients for cardiovascular, malignancy, and liver-related morbidity and mortality. PubMedPubMedCentralCrossRefGoogle Scholar
- 6.Carias S, Castellanos AL, Vilchez V, Nair R, Dela Cruz AC, Watkins J, et al. Nonalcoholic steatohepatitis is strongly associated with sarcopenic obesity in patients with cirrhosis undergoing liver transplant evaluation. J Gastroenterol Hepatol. 2016;31(3):628–33.PubMedPubMedCentralCrossRefGoogle Scholar
- 7.•• Paul S, Charlton M. Surgical issues in NASH: bariatric surgery and liver transplantation. Curr Hepatol Rep. 2018;17(4):367–76 Recent review on the primary effects of bariatric surgery on changes in liver disease severity in NAFLD and NASH patients, including the primary effects of bariatric surgery on metabolic pathways. CrossRefGoogle Scholar
- 11.Tuah NA, Amiel C, Qureshi S, Car J, Kaur B, Majeed A. Transtheoretical model for dietary and physical exercise modification in weight loss management for overweight and obese adults. Cochrane Database Syst Rev. 2011;10:CD008066.Google Scholar
- 12.Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(2):389–97 e10.PubMedPubMedCentralCrossRefGoogle Scholar
- 15.•• Sanyal AJ, Harrison SA, Ratziu V, Abdelmalek MF, Diehl AM, Caldwell S, et al. The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials. Hepatology. 2019; Study of the progression of fibrosis in NASH on multiple levels including Ishak fibrosis stage, hepatic collagen content and alpha-smooth muscle actin, NAFLD activity score, and serum markers for fibrosis. Studied the progression to cirrhosis in patients enrolled in two phase 2b, placebo-controlled trials of simtuzumab. Google Scholar
- 17.•• Kleiner DE, Brunt EM, Belt PH, Wilson L, Guy CD, Yeh MM, et al. Diagnostic pattern and disease activity are related to disease progression and regression in nonalcoholic fatty liver disease. Hepatology. In: WILEY-BLACKWELL 111 RIVER ST, HOBOKEN 07030-5774. NJ: USA; 2016. AASLD summary finding that AST, portal inflammation, baseline fibrosis stage, and NAS are predictors of fibrosis progression or regression, and that fibrosis progression in NAFL patients is linked to evolution of NASH. Google Scholar
- 21.•• Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–57 Latest guidelines from the AASLD regarding management of NAFLD patients. CrossRefGoogle Scholar
- 24.• Greenhalgh S. Soda industry influence on obesity science and policy in China. J Public Health Policy. 2019;40(1):5–16 Excellent review on the soda industry and anti-obesity policy, which is well documented in the US but is now gaining recognition as a global obesity epidemic contributor abroad. PubMedCrossRefPubMedCentralGoogle Scholar
- 25.Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry. 2001.Google Scholar
- 29.•• Hall KD. Did the food environment cause the obesity epidemic? Obesity. 2018;26(1):11–3 Study from the NIDDKD division of the NIH studying how the changing food environment has shaped the obesity epidemic, supporting sensitivity of healthcare systems to policy-level health factors that affect individual patients struggling with weight. PubMedCrossRefGoogle Scholar
- 30.• Phelan SM, Burgess DJ, Yeazel MW, Hellerstedt WL, Griffin JM, van Ryn M. Impact of weight bias and stigma on quality of care and outcomes for patients with obesity. Obes Rev. 2015;16(4):319–26 Critical review of empirical evidence regarding obesity stigma to highlight prejudice in medical care , with potential intervention strategies that may reduce the impact of obesity stigma on quality of care. PubMedPubMedCentralCrossRefGoogle Scholar
- 38.•• van der Windt DJ, Sud V, Zhang H, Tsung A, Huang H. The effects of physical exercise on fatty liver disease. Gene Expression, The Journal of Liver Research. 2018;18(2):89–101 Review summarizing the evidence for effects of physical exercise specifically in NAFLD and NASH patients. CrossRefGoogle Scholar
- 43.• Piercy KL, Troiano RP, Ballard RM, Carlson SA, Fulton JE, Galuska DA, et al. The physical activity guidelines for Americans. Jama. 2018;320(19):2020–8 Summary of key guidelines in the 2018 Physical Activity Guidelines for Americans with specific age and activity goals for physical activity to improve a variety of health outcomes. PubMedCrossRefGoogle Scholar
- 49.•• Do A, Kuszewski EJ, Mehal WZ. Incorporating Weight Loss Medications into Hepatology Practice for Nonalcoholic Steatohepatitis. Hepatology. 2019; Practical considerations for application of weight loss medications into hepatology clinics for NASH patients. Google Scholar
- 50.• Hagström H, Nasr P, Ekstedt M, Hammar U, Stål P, Hultcrantz R, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017;67(6):1265–73 Large study of biopsy-proven NAFLD to study if NASH increased the risk of liver-specific morbidity and overall mortality. CrossRefGoogle Scholar
- 61.Nguyen V, Li J, Gan J, Cordero P, Ray S, Solis-Cuevas A, et al. Outcomes following serial intragastric balloon therapy for obesity and nonalcoholic fatty liver disease in a single centre. Canadian J Gastroenterol Hepatol. 2017;2017.Google Scholar
- 62.•• Dayyeh BKA, Edmundowicz S, Thompson CC. Clinical practice update: expert review on endoscopic bariatric therapies. Gastroenterology. 2017;152(4):716–29 Best practice advice for endoscopic bariatric therapies and their role in part of a structured weight loss program that includes dietary intervention, exercise, and behavior modification throughout weight loss and long-term weight maintenance. PubMedCrossRefGoogle Scholar
- 67.Ikramuddin S, Korner J, Lee W-J, Connett JE, Inabnet WB, Billington CJ, et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. Jama. 2013;309(21):2240–9.PubMedPubMedCentralCrossRefGoogle Scholar
- 75.• Svetkey LP, Stevens VJ, Brantley PJ, Appel LJ, Hollis JF, Loria CM, et al. Comparison of strategies for sustaining weight loss: the weight loss maintenance randomized controlled trial. Jama. 2008;299(10):1139–48 Clinical trial on initial behavioral weight loss programs, finding that monthly brief personal contact provided modest benefit in sustaining weight loss. PubMedCrossRefGoogle Scholar